PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshematologic neoplasms
MeSH D019337 - hematologic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009371:Neoplasms by site
0 Companies
0 Drugs
Success rate
D006402:Hematologic diseases
33 Companies
3 Drugs
$
Success rate
D019337: 
Hematologic neoplasms
4 Companies
1 Drug
$
Success rate
D019046:Bone marrow neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
NovartisMidostaurin Rydapt 2022-10-29 2017-04-28   
Clinical Trials
Historical Success Rate
Phase 1
46%
85/184
Phase 2
18%
24/132
Phase 3
11%
3/27
Approved: 1Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Novartis
Midostaurin,
Aglatimagene besadenovec,
Spartalizumab,
Vatalanib,
Sodium chloride,
Afuresertib,
Bevifimod,
IERAMILIMAB,
Telbermin,
UPROSERTIB,
PIM447,
KRP203,
Sti571,
Arm1,
Arm2,
LGH447,
Taxane
Teva
Ademetionine,
Calcium dobesilate,
Sodium lactate,
Bevifimod,
Microcrystalline cellulose,
Vp16
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use